|
1.
|
Schwartzbaum JA, Fisher JL, Aldape KD and
Wrensch M: Epidemiology and molecular pathology of glioma. Nat Clin
Pract Neurol. 2:494–503. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Stupp R, Hegi ME, Mason WP, Van Den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ,
Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M,
Lacombe D, Cairncross JG and Mirimanoff RO: European Organisation
for Research and Treatment of Cancer Brain Tumour and Radiation
Oncology Groups; National Cancer Institute of Canada Clinical
Trials Group: Effects of radiotherapy with concomitant and adjuvant
temozolomide versus radiotherapy alone on survival in glioblastoma
in a randomised phase III study: 5-year analysis of the EORTC-NCIC
trial. Lancet Oncol. 10:459–466. 2009.
|
|
3.
|
Senger D, Cairncross JG and Forsyth PA:
Long-term survivors of glioblastoma: Statistical aberration or
important unrecognized molecular subtype? Cancer J. 9:214–221.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Liu G, Yuan X, Zeng Z, Tunici P, Ng H,
Abdulkadir IR, Lu L, Irvin D, Black KL and Yu JS: Analysis of gene
expression and chemoresistance of CD133+ cancer stem
cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Brat DJ and Van Meir EG: Glomeruloid
microvascular proliferation orchestrated by VPF/VEGF: A new world
of angiogenesis research. Am J Pathol. 158:789–796. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Brat DJ and Van Meir EG: Vaso-occlusive
and prothrombotic mechanisms associated with tumor hypoxia,
necrosis, and accelerated growth in glioblastoma. Lab Invest.
84:397–405. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Yang L, Lin C, Wang L, Guo H and Wang X:
Hypoxia and hypoxia-inducible factors in glioblastoma multiforme
progression and therapeutic implications. Exp Cell Res.
318:2417–2426. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Harris AL: Hypoxia - a key regulatory
factor in tumor growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Wouters BG, Weppler SA, Koritzinsky M,
Landuyt W, Nuyts S, Theys J, Chiu RK and Lambin P: Hypoxia as a
target for combined modality treatments. Eur J Cancer. 38:240–257.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Nduom EK, Hadjipanayis CG and Van Meir EG:
Glioblastoma cancer stem-like cells: implications for pathogenesis
and treatment. Cancer J. 18:100–106. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Li P, Zhou C, Xu L and Xiao H: Hypoxia
enhances stemness of cancer stem cells in glioblastoma: an in vitro
study. Int J Med Sci. 10:399–407. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Meijer TW, Kaanders JH, Span PN and
Bussink J: Targeting hypoxia, HIF-1, and tumor glucose metabolism
to improve radiotherapy efficacy. Clin Cancer Res. 18:5585–5594.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Wang GL, Jiang BH, Rue EA and Semenza GL:
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS
heterodimer regulated by cellular O2 tension. Proc Natl
Acad Sci USA. 92:5510–5514. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Laderoute KR and Webster KA:
Hypoxia/reoxygenation stimulates Jun kinase activity through redox
signaling in rat cardiac myocytes. Circ Res. 80:336–344. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Laderoute KR, Mendonca HL, Calaoagan JM,
Knapp AM, Giaccia AJ and Stork PJS: Mitogen-activated protein
kinase phosphatase-1 (MKP-1) expression is induced by low oxygen
conditions found in solid tumor microenvironment. J Biol Chem.
274:12890–12897. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Kunz M, Ibrahim S, Koczan D, Thiesen HJ,
Koehler HJ, Acker T, Plate KH, Ludwig S, Rapp UR and Broecker EB:
Activation of c-Jun NH2-terminal kinase/stress-activated protein
kinase (JNK/SAPK) is critical for hypoxia-induced apoptosis of
human malignant melanoma. Cell Growth Differ. 12:137–145.
2001.PubMed/NCBI
|
|
18.
|
Daum G, Eisenmann-Tappe I, Fries HW,
Troppmair J and Rapp UR: The ins and outs of Raf kinases. Trends
Biochem Sci. 19:474–480. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Kunz M and Ibrahim SM: Molecular responses
to hypoxia in tumor cells. Mol Cancer. 17:2–23. 2003.
|
|
20.
|
Lim JH, Lee ES, You HJ, Lee JW, Park JW
and Chun YS: Ras-dependent induction of HIF-1alpha785 via the
Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor
promotion. Oncogene. 23:9427–9431. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Minet E, Arnould T, Michel G, Roland I,
Mottet D, Raes M, Remacle J and Michiels C: ERK activation upon
hypoxia: involvement in HIF-1 activation. FEBS Lett. 468:53–58.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Berra E, Milanini J, Richard DE, Le Gall
M, Vinals F, Gothie E, Roux D, Pages G and Pouyssegur J: Signaling
angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol.
60:1171–1178. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Eastman A and Barry MA: The origins of DNA
breaks: a consequence of DNA damage, DNA repair, or apoptosis?
Cancer Invest. 10:229–240. 1992. View Article : Google Scholar
|
|
24.
|
Chu G: Double strand break repair. J Biol
Chem. 272:24097–24100. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Kanaar R, Hoeijmakers JH and van Gent DC:
Molecular mechanism of DNA double-strand break repair. Trends Cell
Biol. 8:483–489. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Um JH, Kang CD, Bae JH, Shin GG, Kim DW,
Kim DW, Chung BS and Kim SH: Association of DNA-dependent protein
kinase with hypoxia inducible factor-1 and its implication in
resistance to anticancer drugs in hypoxic tumor cells. Exp Mol Med.
36:233–242. 2004. View Article : Google Scholar
|
|
27.
|
Sanson M, Thillet J and Hoang-Xuan K:
Molecular changes in gliomas. Curr Opin Oncol. 16:607–613. 2004.
View Article : Google Scholar
|
|
28.
|
De Groot JF and Gilbert MR: New molecular
targets in malignant gliomas. Curr Opin Neurol. 20:712–718.
2007.PubMed/NCBI
|
|
29.
|
Minniti G, Muni R, Lanzetta G, Marchetti P
and Enrici RM: Chemotherapy for glioblastoma: current treatment and
future perspectives for cytotoxic and targeted agents. Anticancer
Res. 29:5171–5184. 2009.PubMed/NCBI
|
|
30.
|
Marampon F, Gravina GL, Di Rocco A,
Bonfili P, Di Staso M, Fardella C, Polidoro L, Ciccarelli C,
Festuccia C, Popov VM, Pestell RG, Tombolini V and Zani BM: MEK/ERK
inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma
cells in vitro and in vivo by downregulating growth and DNA repair
signals. Mol Cancer Ther. 10:159–168. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Marampon F, Ciccarelli C and Zani BM:
Down-regulation of c-Myc following MEK/ERK inhibition halts the
expression of malignant phenotype in rhabdomyosarcoma and in non
muscle-derived human tumors. Mol Cancer. 5:312006. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Lowry OH, Rosebrough NJ, Farr AL and
Randall RJ: Protein measurement with the Folin phenol reagent. J
Biol Chem. 193:265–275. 1951.PubMed/NCBI
|
|
33.
|
Fukazawa H, Mizuno S and Uehara Y: A
microplate assay for quantitation of anchorage-independent growth
of transformed cells. Anal Biochem. 228:83–90. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Ciccarelli C, Marampon F, Scoglio A, Mauro
A, Giacinti C, De Cesaris P and Zani BM: p21WAF1 expression induced
by MEK/ERK pathway activation or inhibition correlates with growth
arrest, myogenic differentiation and onco-phenotype reversal in
rhabdomyosarcoma cells. Mol Cancer. 4:412005. View Article : Google Scholar
|
|
35.
|
Wilson WR and Hay MP: Targeting hypoxia in
cancer therapy. Nat Rev Cancer. 11:393–410. 2011. View Article : Google Scholar
|
|
36.
|
Jensen RL: Hypoxia in the tumorigenesis of
gliomas and as a potential target for therapeutic measures.
Neurosurg Focus. 20:E242006. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Gupta AK, Bakanauskas VJ, Cerniglia GJ,
Cheng Y, Bernhard EJ, Muschel RJ and McKenna WG: The Ras radiation
resistance pathway. Cancer Res. 61:4278–4282. 2001.PubMed/NCBI
|
|
38.
|
Vordermark D, Katzer A, Baier K, Kraft P
and Flentje M: Cell-type-specific association of hypoxia-inducible
factor-1alpha (HIF-1alpha) protein accumulation and radiobiologic
tumor hypoxia. Int J Radiat Oncol Biol Phys. 58:1242–1250. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Williams KJ, Telfer BA, Xenaki D, Sheridan
MR, Desbaillets I, Peters HJ, Honess D, Harris AL, Dachs GU, van
der Kogel A and Stratford IJ: Enhanced response to radiotherapy in
tumors deficient in the function of hypoxia-inducible factor-1.
Radiother Oncol. 75:89–98. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Dai S, Huang ML, Hsu CY and Chao KS:
Inhibition of hypoxia inducible factor 1alpha causes
oxygen-independent cytotoxicity and induces p53 independent
apoptosis in glioblastoma cells. Int J Radiat Oncol Biol Phys.
55:1027–1036. 2003. View Article : Google Scholar
|
|
41.
|
Sasabe E, Zhou X, Li D, Oku N, Yamamoto T
and Osaki T: The involvement of hypoxia-inducible factor-1alpha in
the susceptibility to gamma-rays and chemotherapeutic drugs of oral
squamous cell carcinoma cells. Int J Cancer. 120:268–277. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Pore N, Gupta AK, Cerniglia GJ, Jiang Z,
Bernard EJ, Evans SM, Koch CJ, Hahn SM and Maity A: Nelfinavir
down-regulates hypoxia-inducible factor 1alpha and VEGF expression
and increases tumor oxygenation: implications for radiotherapy.
Cancer Res. 66:9252–9259. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Tian X, Chen G, Xing H, Weng D, Guo Y and
Ma D: The relationship between the down-regulation of DNA-PKcs or
Ku70 and the chemosensitization in human cervical carcinoma cell
line HeLa. Oncol Rep. 18:927–32. 2007.PubMed/NCBI
|
|
44.
|
Chang HW, Kim SY, Yi SL, Son SH, Song do
Y, Moon SY, Kim JH, Choi EK, Ahn SD, Shin SS, Lee KK and Lee SW:
Expression of Ku80 correlates with sensitivities to radiation in
cancer cell lines of the head and neck. Oral Oncol. 42:979–986.
2006. View Article : Google Scholar : PubMed/NCBI
|
